Johnson & Johnson Comments on Venezuelan Currency Devaluation

        Johnson & Johnson Comments on Venezuelan Currency Devaluation

PR Newswire

NEW BRUNSWICK, N.J., Feb. 25, 2013

NEW BRUNSWICK, N.J., Feb. 25, 2013 /PRNewswire/ --Johnson & Johnson (NYSE:
JNJ) today announced that based on its preliminary assessment of the impact of
the Venezuelan government's decision to devalue its currency effective Feb.
13, 2013, that it expects to incur a charge of approximately $100 million to
Net Income in the First Quarter of 2013 or approximately a $0.04 negative
impact to earnings per share. This charge is related to the remeasurement of
the local balance sheet at the date of the devaluation and is not expected to
impact earnings per share guidance for full-year 2013 which was previously
announced on January 22, 2013.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 127,600 employees at more than 275 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson & Johnson.
Risks and uncertainties include, but are not limited to, general industry
conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and
patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; challenges to patents;
significant adverse litigation or government action; impact of business
combinations; financial distress and bankruptcies experienced by significant
customers and suppliers; changes to governmental laws and regulations and
domestic and foreign health care reforms; trends toward health care cost
containment; increased scrutiny of the health care industry by government
agencies; changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international economies
and sovereign risk; disruptions due to natural disasters; manufacturing
difficulties or delays; complex global supply chains with increasing
regulatory requirements; and product efficacy or safety concerns resulting in
product recalls or regulatory action. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended December 30,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at,  or on request from Johnson &
Johnson. Johnson & Johnson does not undertake to update any forward-looking
statements as a result of new information or future events or developments.)

SOURCE Johnson & Johnson

Contact: Press: Carol Goodrich, +1-732-524-6678, +1-973-615-4057 (M), or Al
Wasilewski, +1-732-524-1130, +1-732-447-5918 (M), or Investor Contacts: Louise
Mehrotra, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, or Lesley
Fishman, +1-732-524-3922, or Ellen Sipos, +1-732-524-3709
Press spacebar to pause and continue. Press esc to stop.